PMV Pharmaceuticals opened lower at $1.25, compared with its previous close of $1.26. In the last trading session, the stock traded between $1.18 and $1.27. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in PMV Pharmaceuticals is now worth
$ 5.13
Resulting in a loss of
$ 94.87 (94.87%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.05 (-3.57%)
Day High
$1.27
Day Low
$1.18
Day Open
$1.25
Prev Close
$1.26
Volume
3,34,133
1W Return
-8.09%
1M Return
-13.52%
3M Return
-6.90%
6M Return
-12.59%
1Y Return
-8.65%
Fundamentals
Market Cap ($ Mn)
92
PE Ratio
-
PB Ratio
0.91
PEG Ratio
-
ROE
-55.33%
ROCE
-61.11%
EPS (TTM)
$-0.46
Investment Returns
1 Week
-8.09%
1 Month
-13.52%
3 Months
-6.90%
6 Months
-12.59%
9 Months
8.48%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
1Sep
PMV Pharma prices $50.8M offering as it plans rezatapopt NDA submission
PMV Pharma priced a $50.8 million oversubscribed public offering. Company plans to submit NDA for rezatapopt in Q1 2027. Phase 2 trial showed 46% overall response rate in ovarian cancer patients. Shares fell 10.74% to $1.08 in premarket trading.
2mo ago
1Sep
PMV Pharma reports 46% response rate for rezatapopt in ovarian cancer trial
PMV Pharma reports 46% overall response rate for rezatapopt in 76 ovarian cancer patients. Median duration of response reached 10.0 months with rapid onset at 1.3 months. FDA feedback supports NDA submission strategy for accelerated approval. Company plans NDA filing in first quarter of 2027. Safety profile remains favorable with only 5% discontinuation due to adverse events.
2mo ago
14Aug
PMV Pharma Q2 Results: Net Loss Narrows To $18.1 Million
PMV Pharmaceuticals reported Q2 2026 results with a net loss of $18.1 million, improved from $21.2 million YoY due to lower R&D and G&A costs. The company completed enrollment for its Phase 2 PYNNACLE trial and plans an NDA submission for rezatapopt in Q1 2027. Cash reserves stand at $79.4 million.
